Description du projet
De nouveaux médicaments qui surmontent la résistance aux antibiotiques pourraient entrer en phase d’essai clinique
Les bactéries Gram-négatives ont une membrane externe qui empêche la pénétration des antibiotiques. L’augmentation de la résistance à plusieurs médicaments chez les bactéries Gram-négatives est en train de devenir un défi majeur pour la santé publique et le projet GNA NOW, financé par l’UE, se prépare à le relever. Dans le cadre du nouveau programme sur la résistance aux antimicrobiens (RAM) de l’UE, des universitaires et des experts du secteur envisagent de découvrir et de tester les composés antibiotiques les plus prometteurs au cours des six prochaines années et de les soumettre à des essais cliniques.
Objectif
AntiMicrobial Resistance (AMR) is a global and serious threat to human health. Gram-negative bacteria are widely regarded as the culprit representing one of the gravest dangers. Indeed, there is a dearth of new agents able to address AMR in Gram-negative bacteria, especially compounds with novel modes of action. Finding and developing such compounds represents a huge scientific challenge, one that requires the collaboration of stakeholders bringing many different kinds of expertise. The world is coming together to tackle this issue and public-private partnerships represent an attractive way to hasten the pace and increase the probability of successfully identifying and developing novel antibiotics.
Under the global umbrella of the AMR Accelerator, the Gram-Negative Antibacterials-NOW (GNA NOW) consortium pledges to a 6-years commitment to bring together key European academic and private experts in antibiotic discovery and development in order to support and manage a portfolio of novel mode of action drugs against Gram-negative bacteria. Starting with three initial compounds/series, dedicated project teams will work together to define and execute the most efficient project plans. The consortium will put in place robust governance and management structures to ensure that the most promising compounds are pursued diligently. Ultimately, the goal of GNA NOW is to progress one compound through completion of phase I studies plus one compound reaching Investigational New Drug (IND) stage and/or up to two compounds reaching clinical development candidate stage.
Champ scientifique
Programme(s)
Régime de financement
RIA - Research and Innovation actionCoordinateur
3521 AL Utrecht
Pays-Bas
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.